119 related articles for article (PubMed ID: 38513729)
1. Synthesis and characterisation of a nucleotide based pro-drug formulated with a peptide into a nano-chemotherapy for colorectal cancer.
Wilson JJ; Bennie L; Eguaogie O; Elkashif A; Conlon PF; Jena L; McErlean E; Buckley N; Englert K; Dunne NJ; Tucker JHR; Vyle JS; McCarthy HO
J Control Release; 2024 May; 369():63-74. PubMed ID: 38513729
[TBL] [Abstract][Full Text] [Related]
2. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
Ladner RD; Lynch FJ; Groshen S; Xiong YP; Sherrod A; Caradonna SJ; Stoehlmacher J; Lenz HJ
Cancer Res; 2000 Jul; 60(13):3493-503. PubMed ID: 10910061
[TBL] [Abstract][Full Text] [Related]
3. Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
Liu ZY; Tang ML; Ning JF; Hao YP; Zhou L; Sun X
Eur J Med Chem; 2020 May; 193():112194. PubMed ID: 32203786
[TBL] [Abstract][Full Text] [Related]
4. Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin in Human Colorectal Cancer Xenografts in Nude Mice.
Li X; Xia L; Ouyang X; Suyila Q; Su L; Su X
Protein Pept Lett; 2019; 26(7):512-522. PubMed ID: 30950338
[TBL] [Abstract][Full Text] [Related]
5. Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA.
Massey AS; Pentlavalli S; Cunningham R; McCrudden CM; McErlean EM; Redpath P; Ali AA; Annett S; McBride JW; McCaffrey J; Robson T; Migaud ME; McCarthy HO
Mol Pharm; 2016 Apr; 13(4):1217-28. PubMed ID: 26954700
[TBL] [Abstract][Full Text] [Related]
6. Novel opportunities for thymidylate metabolism as a therapeutic target.
Wilson PM; Fazzone W; LaBonte MJ; Deng J; Neamati N; Ladner RD
Mol Cancer Ther; 2008 Sep; 7(9):3029-37. PubMed ID: 18790783
[TBL] [Abstract][Full Text] [Related]
7. Engineering lauric acid-based nanodrug delivery systems for restoring chemosensitivity and improving biocompatibility of 5-FU and OxPt against
Su M; Wen X; Yu Y; Li N; Li X; Qu X; Elsabahy M; Gao H
J Mater Chem B; 2024 Apr; 12(16):3947-3958. PubMed ID: 38586917
[TBL] [Abstract][Full Text] [Related]
8. Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment.
Jin Y; Yang F; Du L
Colloids Surf B Biointerfaces; 2013 Dec; 112():421-8. PubMed ID: 24036626
[TBL] [Abstract][Full Text] [Related]
9. Polymer-based nanoparticles for chemo/gene-therapy: Evaluation its therapeutic efficacy and toxicity against colorectal carcinoma.
Chen Y; Li N; Xu B; Wu M; Yan X; Zhong L; Cai H; Wang T; Wang Q; Long F; Jiang G; Xiao H
Biomed Pharmacother; 2019 Oct; 118():109257. PubMed ID: 31377472
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
Naghibalhossaini F; Shefaghat M; Mansouri A; Jaberi H; Tatar M; Eftekhar E
Acta Med Iran; 2017 Dec; 55(12):751-758. PubMed ID: 29373881
[TBL] [Abstract][Full Text] [Related]
11. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides.
Hong ST; Lin H; Wang CS; Chang CH; Lin AM; Yang JC; Lo YL
J Nanobiotechnology; 2019 Aug; 17(1):89. PubMed ID: 31426807
[TBL] [Abstract][Full Text] [Related]
12. Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
Alzoubi S; Brody L; Rahman S; Mahul-Mellier AL; Mercado N; Ito K; El-Bahrawy M; Silver A; Boobis A; Bell JD; Hajji N
Oncotarget; 2016 Jul; 7(28):44505-44521. PubMed ID: 27283986
[TBL] [Abstract][Full Text] [Related]
13. Application of smart solid lipid nanoparticles to enhance the efficacy of 5-fluorouracil in the treatment of colorectal cancer.
Smith T; Affram K; Nottingham EL; Han B; Amissah F; Krishnan S; Trevino J; Agyare E
Sci Rep; 2020 Oct; 10(1):16989. PubMed ID: 33046724
[TBL] [Abstract][Full Text] [Related]
14. Tumor vasculature-targeting PEGylated peptide-drug conjugate prodrug nanoparticles improve chemotherapy and prevent tumor metastasis.
Hao T; Fu Y; Yang Y; Yang S; Liu J; Tang J; Ridwan KA; Teng Y; Liu Z; Li J; Guo N; Yu P
Eur J Med Chem; 2021 Jul; 219():113430. PubMed ID: 33865152
[TBL] [Abstract][Full Text] [Related]
15. Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells.
Sundaramoorthy P; Ramasamy T; Mishra SK; Jeong KY; Yong CS; Kim JO; Kim HM
Acta Biomater; 2016 Sep; 42():220-231. PubMed ID: 27395829
[TBL] [Abstract][Full Text] [Related]
16. ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
Narayan S; Ramisetti S; Jaiswal AS; Law BK; Singh-Pillay A; Singh P; Amin S; Sharma AK
Eur J Med Chem; 2019 Jan; 161():456-467. PubMed ID: 30384048
[TBL] [Abstract][Full Text] [Related]
17. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future.
Vodenkova S; Buchler T; Cervena K; Veskrnova V; Vodicka P; Vymetalkova V
Pharmacol Ther; 2020 Feb; 206():107447. PubMed ID: 31756363
[TBL] [Abstract][Full Text] [Related]
18. dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA-repair-defective human cancer cells.
Yokogawa T; Yano W; Tsukioka S; Osada A; Wakasa T; Ueno H; Hoshino T; Yamamura K; Fujioka A; Fukuoka M; Ohkubo S; Matsuo K
Cancer Sci; 2021 Jan; 112(1):422-432. PubMed ID: 33140501
[TBL] [Abstract][Full Text] [Related]
19. Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition.
Koehler SE; Ladner RD
Mol Pharmacol; 2004 Sep; 66(3):620-6. PubMed ID: 15322254
[TBL] [Abstract][Full Text] [Related]
20. Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment.
Zhang W; Li C; Shen C; Liu Y; Zhao X; Liu Y; Zou D; Gao Z; Yue C
Drug Deliv; 2016 Sep; 23(7):2575-2580. PubMed ID: 26056720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
